TET2 and Miyoshi myopathy: Utilizing WGS, today’s most comprehensive genomic analysis tool, additional de novo mutations (e.g., FAM46C, TRAF2, NF1, and XBP1), de novo translocations (MAP3K14), pre-existing (e.g., Tet2) and non-coding mutations (Xbp-1, SCML1, and RBX1) have been identified at MM relapse [83].